retina

Novel anti-VEGF-A agent shows promise for prolonged DME activityAbicipar pegol (Allergan/Molecular Partners) met its primary and key secondary endpoints and demonstrated an acceptable overall safety profile in a phase II trial investigating use of the novel anti-VEGF-A agent for treatment of diabetic macular edema (DME).
New research, interest advancing retinal careTreatment of posterior segment disease is in the midst of a paradigm shift, says a panel of experts at this year's annual SECO 2017 conference in Atlanta.
Expanded line of 27-gauge instruments advantageous
Expanded line of 27-gauge instruments advantageousThe portfolio of retinal instruments continues to expand with a growing line of tools offering surgeons improved work efficiency while promoting better surgical outcomes with 27-gauge instruments.
Global diabetes epidemic must not become epidemic of blindnessThe global epidemic in type 2 diabetes mellitus is of unprecedented proportions. In absolute numbers, it probably exceeds any previous epidemic in the history of mankind. There are now more than 400 million people with diabetes in the world, and the number is projected to exceed 600 million by 2030.
Flanged fixation secures IOL haptics within the scleraFlanged IOL fixation is a simple, minimally invasive, and effective technique for transconjunctival intrascleral fixation of a three-piece IOL, said Shin Yamane, MD, PhD, at the inaugural Retina World Congress.
Strategies for macular hole recurrence after small-gauge vitrectomyFindings from a retrospective review provide insights about the outcomes of surgery for recurrent macular holes in the era of small-gauge vitrectomy and possible strategies for reducing their occurrence, said Tarek S. Hassan, MD, at the inaugural Retina World Congress.
Effective drug management of PVR remains unfulfilled goalThe bottom line about pharmaceutical management of proliferative vitreoretinopathy (PVR) is that many different drugs have been tried, but so far nothing has been proven effective for treating PVR or reducing its risk, said Demetrios G. Vavvas, MD, PhD, at the inaugural Retina World Congress.
Research limited on role of combination therapy for CRVO-related MECombination therapy may be a reasonable approach to manage eyes that are not responding to intravitreal monotherapy with an anti-vascular endothelial growth factor (VEGF) agent or corticosteroid, said Lihteh Wu, MD, at the inaugural Retina World Congress.
Improving vision with electronic retinal implantsElectronic retina implants can restore enough vision for some patients to pursue tasks of daily living, according to RE MacLaren, part of a team testing the devices.
Treatment for geographic atrophy lacks efficacy in Phase 2 studyIn a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.